DE69726450D1 - Mucosale verabreichung von wirkstoffen in säugern - Google Patents
Mucosale verabreichung von wirkstoffen in säugernInfo
- Publication number
- DE69726450D1 DE69726450D1 DE69726450T DE69726450T DE69726450D1 DE 69726450 D1 DE69726450 D1 DE 69726450D1 DE 69726450 T DE69726450 T DE 69726450T DE 69726450 T DE69726450 T DE 69726450T DE 69726450 D1 DE69726450 D1 DE 69726450D1
- Authority
- DE
- Germany
- Prior art keywords
- mammals
- mucosal administration
- active substances
- natural polymer
- biovector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
- Y10S977/783—Organic host/matrix, e.g. lipid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/80—Nucleic acid, e.g. DNA or RNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/827—Nanostructure formed from hybrid organic/inorganic semiconductor compositions
- Y10S977/83—Inorganic core or cluster coated with organic or biological shell
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y10S977/917—Vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/774,920 US6096291A (en) | 1996-12-27 | 1996-12-27 | Mucosal administration of substances to mammals |
US774920 | 1996-12-27 | ||
PCT/IB1997/001647 WO1998029099A2 (en) | 1996-12-27 | 1997-12-09 | Mucosal administration of substances to mammals |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69726450D1 true DE69726450D1 (de) | 2004-01-08 |
DE69726450T2 DE69726450T2 (de) | 2004-09-16 |
Family
ID=25102698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69726450T Expired - Fee Related DE69726450T2 (de) | 1996-12-27 | 1997-12-09 | Mucosale verabreichung von wirkstoffen in säugern |
Country Status (15)
Country | Link |
---|---|
US (2) | US6096291A (de) |
EP (1) | EP0948322B1 (de) |
JP (1) | JP2001507358A (de) |
KR (1) | KR20000062350A (de) |
AT (1) | ATE254911T1 (de) |
AU (1) | AU739512B2 (de) |
BR (1) | BR9713792A (de) |
CA (1) | CA2275419C (de) |
DE (1) | DE69726450T2 (de) |
DK (1) | DK0948322T3 (de) |
ES (1) | ES2212145T3 (de) |
HK (1) | HK1025042A1 (de) |
HU (1) | HUP0001838A3 (de) |
IL (1) | IL130507A0 (de) |
WO (1) | WO1998029099A2 (de) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
DK1039931T3 (da) * | 1997-12-01 | 2005-08-08 | Fang Fang | Multivalente rekombinante antistoffer til at behandle HRV infektioner |
FR2771929B1 (fr) * | 1997-12-09 | 2001-02-23 | Biovector Therapeutics | Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central |
US7097849B2 (en) * | 1998-08-19 | 2006-08-29 | Jagotec Ag | Injectable aqueous dispersions of propofol |
US20070178139A1 (en) * | 1998-11-18 | 2007-08-02 | Yankov Vladimir I | Vaginally administratable progesterone-containing tablets and method for preparing same |
IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
US20030035798A1 (en) * | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
EP2481401A1 (de) | 1999-01-18 | 2012-08-01 | LG Life Sciences, Ltd. | Lipophile Mikropartikel mit einem Proteinarzneimittel oder Antigen und Formulierung damit |
US20050232868A1 (en) * | 1999-10-19 | 2005-10-20 | The Procter & Gamble Company | Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions |
US20040234457A1 (en) * | 1999-10-19 | 2004-11-25 | The Procter & Gamble Company | Methods of preventing and treating SARS using low pH respiratory tract compositions |
US7785625B2 (en) | 2000-01-14 | 2010-08-31 | Lg Life Sciences, Limited | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
WO2001068828A2 (en) | 2000-03-13 | 2001-09-20 | Engene, Inc. | Compositions and methods for regulated protein expression in gut |
WO2001070763A1 (en) * | 2000-03-22 | 2001-09-27 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
FR2808193B1 (fr) * | 2000-04-26 | 2004-05-07 | Biovector Therapeutics | Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers |
EP1276468A1 (de) * | 2000-04-26 | 2003-01-22 | Biovector Therapeutics S.A. | Verwendung teilchenförmiger vektoren in der immunomodulation |
DE60128910T2 (de) | 2000-04-27 | 2008-02-28 | Verion Inc. | Nullte-ordnung-freisetzung und temperatur-kontrollierte mikrokapseln sowie herstellungsverfahren |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US6368602B1 (en) * | 2000-06-16 | 2002-04-09 | Hadasit Medical Research Services And Development Ltd | Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine |
US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
EP1343581A2 (de) | 2000-09-27 | 2003-09-17 | Verion Inc. | Sofortige wasserlösliche kapsel und ihr herstellungsverfahren |
US20020150621A1 (en) * | 2000-10-16 | 2002-10-17 | Kohane Daniel S. | Lipid-protein-sugar particles for drug delivery |
WO2002032396A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for delivery of nucleic acids |
US6663861B2 (en) | 2000-11-09 | 2003-12-16 | Antibodyshop A/S | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins |
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
WO2002041827A2 (en) | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
EP1353556A4 (de) * | 2001-01-23 | 2009-09-09 | Massachusetts Inst Technology | Fest- und flüssigphasen-synthese von heparin und anderen glykosaminoglykanen |
JP2004517103A (ja) * | 2001-02-26 | 2004-06-10 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | 薬剤、治療用ペプチド/タンパク質およびワクチンの経口送達のための新規なビタミンb12−生物分解性微粒子状接合体キャリヤー系 |
GB0106403D0 (en) * | 2001-03-15 | 2001-05-02 | Pharmaceutical Profiles | Labelling of dry powder formulations for inhalation |
CA2898314A1 (en) | 2001-07-19 | 2003-07-31 | Perian Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
MXPA04005865A (es) | 2001-12-19 | 2004-09-13 | Nektar Therapeutics | Suministro de aminoglucosidos a los pulmones. |
DE10200717A1 (de) | 2002-01-10 | 2003-07-31 | Knoell Hans Forschung Ev | Verwendung von Polysaccharid-Derivaten als antiinfektive Substanzen |
US20050170334A1 (en) * | 2002-03-13 | 2005-08-04 | Toshifumi Mikayama | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
AU2003223285A1 (en) * | 2002-03-13 | 2003-09-29 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
US7943179B2 (en) * | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
US20050123596A1 (en) * | 2003-09-23 | 2005-06-09 | Kohane Daniel S. | pH-triggered microparticles |
US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
US7807847B2 (en) * | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
EP2574612A1 (de) | 2004-07-09 | 2013-04-03 | Vascular Biogenics Ltd. | Verbessertes Verfahren zur Herstellung von oxidierten Phospholipiden |
CA2606386C (en) * | 2005-04-29 | 2014-06-10 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
WO2006131023A1 (en) * | 2005-06-08 | 2006-12-14 | Newbiomed Pika Pte Ltd | Polyinosinic acid-polycytidylic acid-based adjuvant |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
WO2007065118A2 (en) * | 2005-12-01 | 2007-06-07 | Innograft, Llc | Method for ionically cross-linking polysaccharide material for thin film applications and products produced therefrom |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
EP1897538A1 (de) * | 2006-08-23 | 2008-03-12 | Stallergenes Sa | Formulierungen für Antigen-spezifische Toleranzinduktion |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
BRPI0905725B8 (pt) | 2008-01-11 | 2021-05-25 | Univ Emory | vacina e embalagem farmacêutica |
EP2348866B1 (de) * | 2008-11-06 | 2015-01-07 | Vascular Biogenics Ltd. | Oxidierte lipidverbindungen und ihre verwendung |
WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
AU2010279492B2 (en) | 2009-08-04 | 2015-04-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of The Health And Human Services, Centers For Disease Control And Prevention | Anti-RSV immunogens and methods of immunization |
WO2011060233A1 (en) | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
EP2506859B1 (de) * | 2009-12-04 | 2016-05-04 | Magle AB | Mikrokugeln aus hydrolysierter stärke mit endogenen geladenen liganden |
WO2011100408A2 (en) | 2010-02-10 | 2011-08-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Centers For Disease Control And Prevention | Serologic correlates of protection against bacillis anthracis infection |
US9102742B2 (en) | 2010-02-10 | 2015-08-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Serologic correlates of protection against Bacillus anthracis infection |
AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
EP2691530B1 (de) | 2011-06-10 | 2018-03-07 | Oregon Health & Science University | Cmv-glycoproteine und rekombinante vektoren |
US8514067B2 (en) | 2011-08-16 | 2013-08-20 | Elwha Llc | Systematic distillation of status data relating to regimen compliance |
EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
US8965062B2 (en) * | 2011-09-16 | 2015-02-24 | The Invention Science Fund I, Llc | Reporting imaged portions of a patient's body part |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
ES2855299T3 (es) | 2014-11-26 | 2021-09-23 | Vascular Biogenics Ltd | Lípidos oxidados y tratamiento o prevención de la fibrosis |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN109142420B (zh) * | 2018-10-12 | 2020-01-10 | 厦门大学 | 基于核磁共振技术探究药物在胶束内最大增溶量的方法 |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
FR3112284B1 (fr) | 2020-07-10 | 2024-02-09 | Vaxinano | Procede de preparation d’une composition vaccinale a partir d’antigenes lyophilises |
IT202200004892A1 (it) | 2022-03-14 | 2023-09-14 | Sissa Scuola Int Superiore Di Studi Avanzati | Dispositivo per l’erogazione di farmaci a base di grafene per la somministrazione mucosale e transmucosale |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148876A (en) * | 1975-09-29 | 1979-04-10 | Burroughs Wellcome Co. | Biological preparations |
GB1564500A (en) * | 1975-09-29 | 1980-04-10 | Wellcome Found | Biological preparations |
US4196191A (en) * | 1975-09-29 | 1980-04-01 | Burroughs Wellcome Co. | Biological preparations |
US4921757A (en) * | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
US4900556A (en) * | 1985-04-26 | 1990-02-13 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
US4925678A (en) * | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
DE3722837A1 (de) * | 1987-07-10 | 1989-01-19 | Ruetgerswerke Ag | Ophthalmisches depotpraeparat |
FR2631826B1 (fr) * | 1988-05-27 | 1992-06-19 | Centre Nat Rech Scient | Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation |
GB9018690D0 (en) * | 1990-08-24 | 1990-10-10 | Wellcome Found | Vaccines |
DE4120760A1 (de) * | 1991-06-24 | 1993-03-04 | 3 M Medica Gmbh | Traegersysteme fuer arzneimittel |
FR2702160B1 (fr) * | 1993-03-02 | 1995-06-02 | Biovecteurs As | Vecteurs particulaires synthétiques et procédé de préparation. |
US5354853A (en) * | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
FR2704145B1 (fr) * | 1993-04-21 | 1995-07-21 | Pasteur Institut | Vecteur particulaire et composition pharmaceutique le contenant. |
FR2723849B1 (fr) * | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
ES2170853T3 (es) * | 1995-03-28 | 2002-08-16 | Fidia Advanced Biopolymers Srl | Nanosferas que comprenden un polisacarido biocompatible. |
-
1996
- 1996-12-27 US US08/774,920 patent/US6096291A/en not_active Expired - Fee Related
-
1997
- 1997-12-09 AU AU56756/98A patent/AU739512B2/en not_active Ceased
- 1997-12-09 EP EP97953010A patent/EP0948322B1/de not_active Expired - Lifetime
- 1997-12-09 ES ES97953010T patent/ES2212145T3/es not_active Expired - Lifetime
- 1997-12-09 US US08/987,436 patent/US6017513A/en not_active Expired - Fee Related
- 1997-12-09 DE DE69726450T patent/DE69726450T2/de not_active Expired - Fee Related
- 1997-12-09 JP JP52977498A patent/JP2001507358A/ja active Pending
- 1997-12-09 IL IL13050797A patent/IL130507A0/xx unknown
- 1997-12-09 AT AT97953010T patent/ATE254911T1/de not_active IP Right Cessation
- 1997-12-09 HU HU0001838A patent/HUP0001838A3/hu unknown
- 1997-12-09 WO PCT/IB1997/001647 patent/WO1998029099A2/en active IP Right Grant
- 1997-12-09 CA CA002275419A patent/CA2275419C/en not_active Expired - Fee Related
- 1997-12-09 DK DK97953010T patent/DK0948322T3/da active
- 1997-12-09 BR BR9713792-8A patent/BR9713792A/pt unknown
- 1997-12-09 KR KR1019997005831A patent/KR20000062350A/ko not_active Application Discontinuation
-
2000
- 2000-04-13 HK HK00102267A patent/HK1025042A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP0001838A2 (hu) | 2000-10-28 |
WO1998029099A2 (en) | 1998-07-09 |
JP2001507358A (ja) | 2001-06-05 |
DK0948322T3 (da) | 2004-03-29 |
CA2275419C (en) | 2006-10-03 |
AU5675698A (en) | 1998-07-31 |
EP0948322A2 (de) | 1999-10-13 |
ATE254911T1 (de) | 2003-12-15 |
US6096291A (en) | 2000-08-01 |
HK1025042A1 (en) | 2000-11-03 |
CA2275419A1 (en) | 1998-07-09 |
US6017513A (en) | 2000-01-25 |
EP0948322B1 (de) | 2003-11-26 |
AU739512B2 (en) | 2001-10-11 |
BR9713792A (pt) | 2000-02-08 |
ES2212145T3 (es) | 2004-07-16 |
IL130507A0 (en) | 2000-06-01 |
WO1998029099A3 (en) | 1998-09-17 |
KR20000062350A (ko) | 2000-10-25 |
DE69726450T2 (de) | 2004-09-16 |
HUP0001838A3 (en) | 2000-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69726450D1 (de) | Mucosale verabreichung von wirkstoffen in säugern | |
FI971776A0 (fi) | Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi | |
IT1286501B1 (it) | Borati stabili agli acidi per la fotopolimerizzazione | |
EE9900481A (et) | Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks | |
ES2044957T3 (es) | Metodo para obtener una preparacion para administracion intranasal. | |
LU91758I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
ES2187659T3 (es) | Tratamiento de la diabetes mellitus de tipo ii con agonistas de amilina. | |
DE69636104D1 (de) | Orale pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreigabe von Protonenpumpen-Hemmern | |
EA200000449A1 (ru) | Модифицированные витамины к-зависимые полипептиды | |
DK0785948T3 (da) | Analoger af keratinocyt vækstfaktor | |
FI885533A0 (fi) | Polymerkomposition foer anvaendning som belaeggning foer elledningar och foerfarande foer belaeggning av elledningar. | |
EP0360077A3 (de) | Verwendung von Serotonin-Antagonisten bei der Behandlung von Apoplexia cerebri | |
BR9808641B1 (pt) | processo para preparação de uma forma de dosagem sólida, oral de rápida desintegração de uma substáncia farmaceuticamente ativa que possui um sabor inaceitável. | |
DK1167354T3 (da) | Racemisk huperzin A | |
KR950700725A (ko) | 리포솜 조성물(liposome composition) | |
EA199900580A1 (ru) | Фармацевтические производные аминофосфоновой кислоты | |
IT8224665A0 (it) | Acidi alfa-arilalcanoici e loro derivati in forma otticamente attiva, particolarmente utili come medicamenti e procedimento per laloro preparazione. | |
NO963749D0 (no) | Transdermalt system i form av et plaster med et Tamoxifenderivat | |
IT1319275B1 (it) | Uso del baclofen nel trattamento dell'astinenza da etanolo. | |
FI935051A (fi) | Lanolinderivat som penetrationfraemjande aemnen och anvaendning av dessa i preparat innehaollande laekemedel eller andra biologiskt aktiva substanser | |
YU12397A (en) | NOVEL PYRIMIDO [1,2-a] INDOLES | |
AR017216A1 (es) | Metodo para regular la fagocitosis de celulas de mamiferos. | |
ES2136724T3 (es) | Emulsion liofilizada, que contiene una sustancia activa. | |
ES2131308T3 (es) | Composiciones y metodos que utilizan el receptor de mpl no ligado para estimular la produccion de plaquetas. | |
NO975127L (no) | Anvendelse av ikke-steroidale antiinflammatoriske midler for å forbedre den fysiologiske forlikelighet av partikulære farmasöytiske preparater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |